Biotech China 2014

View Profile


Grant Support

Start year End year Title Source Position
1. 2010 2013 GPCR-targeting multivalent nanoparticles for characterization of circulating tumor cells NIH-DHHS-US-10-PAF04408 Participating Investigator with Specified Effort
2. 2010 2013 Heterobifacial dendrimer and novel polyvalent tumor-targeted nanomedicine NIH-DHHS-US-10-PAF04474 Participating Investigator with Specified Effort
3. 2010 2013 Combinatorial Dendron Nanoparticle Scaffolds for Cancer and Inflammatory Disease Diagnosis and Treatment NIH-DHHS-US-10-PAF04981 UM Principal Investigator
4. 2010 2013 Nanoemulsion-based anti-microbials to prevent and treat burn and traumatic wound infections NIH-DHHS-US-10-PAF04972 UM Principal Investigator
5. 2010 2013 Nanoemulsion-based anti-microbials for protection against burn and wound infections Army-DoD-US-10-PAF04280. UM Principal Investigator
6. 2009 2013 EFRI-BioSAl: Engineering Synthetic Mimics of DNA-Protein Recognition Systems NSF-US-09-PAF02191 Participating Investigator with Specified Effort
7. 2012 Imaging and Drug Delivery for Inflammatory Arthritis NIH NIBIB 12-PAF01079. PD/PI
8. 2010 2012 Phase III: Battlefield Analgesics with Physiological Feedback Control - Supplement Revision DARPA-DoD-US through a consortium with Army-DoD-US-10-PAF05421. UM Principal Investigator
9. 2009 2012 Respiratory Syncytial Virus Vaccine Gates, Bill and Melinda, Found through a consortium with NanoBio Corporation-10-PAF00344. UM Principal Investigator
10. 2009 2012 MRI: Acquisition of an Ultrahigh Resolution Electron-beam Lithography System for the University of Michigan Lurie Nanofabrication Facility NSF-US-09-PAF00466. Participating Investigator with Specified Effort
11. 2007 2012 Primate Testing of a Novel Mucosal Smallpox Vaccine SubK-NIH-DHHS-US through a consortium with University of Chicago-06-1889 .
12. 2007 2012 Neuraminidase-Deficient Influenza Vaccines with Nanoemulsions as Adjuvants SubK-NIH-DHHS-US through a consortium with University of Wisconsin-07-4515. UM Principal Investigator
13. 2006 2012 University of Michigan Comprehensive Cancer Center Support Grant NIH-DHHS-US-05-4873. Participating Investigator with Specified Effort
14. 2011 Apoptosis in Thyroiditis NIH-DHHS-US-10-PAF03930 UM Principal Investigator
15. 2011 Targeting Ovarian Tumor Associated Myeloid Cells with Nanoparticles Therapeutics to Overcome Anti-VEGF Resistance and Restrict Ovarian Cancer Stem Cell Growth NIH-DHHS-US-11-PAF03689 Participating Investigator with Specified Effort
16. 2011 Dendrimers Containing a Precisely Defined Ligand/Particle Ratio NIH-DHHS-US-11-PAF00891 Participating Investigator with Specified Effort
17. 2010 2011 Nanoemulsion-based Vaccine for Chronic Hepatitis B Virus SubK-NIH-DHHS-US through a consortium with NanoBio Corporation-09-PAF01859 UM Principal Investigator
18. 2010 The Role of Cell Membrane Disruption in Non-Viral Vector Oligonucleotide Delivery DHHS-US-10-PAF02174 Participating Investigator with Specified Effort
19. 2010 Flagellin Stimulates Lung Innate Mucosal Immunity NIH-DHHS-US-10-PAF00267 Participating Investigator with Specified Effort
20. 2010 Dendritic Polymer Based, MRI-Guided, Targeted Drug Delivery for Cancer Therapy NIH-DHHS-US-10-PAF03973 Participating Investigator with Specified Effort
21. 2009 2010 DNA-Linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment NIH-DHHS-US-09-PAF03729. UM Principal Investigator
22. 2008 2010 Phase II: Battlefield Analgesics with Physiological Feedback Control DARPA-DoD-US-08-5054 UM Principal Investigator
23. 2007 2010 MRI: Acquisition of Monochromated, Aberration-corrected, Ultra High Resolution Transmission Electron Microscope for the University of Michigan's Electron Microbeam Analysis Laboratory NSF-US-07-3141 Participating Investigator with Specified Effort
24. 2006 2010 The Interaction of Polycationic Organic Polymers with Biological Membranes NIH-DHHS-US-06-3596 Participating Investigator with Specified Effort
25. 2006 2010 Tumor-Targeted Silencing of Bcl-2/Bcl-xL by the Self-Assembled siRNA Nanovectors NIH-DHHS-US-06-0592 Participating Investigator with Specified Effort
26. 2005 2010 Nanoemulsions as Adjuvants for Nasal-Spray Vaccines Gates, Bill and Melinda, Found-04-5010. UM Principal Investigator
27. 2005 2010 DNA-Linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment NIH-DHHS-US-05-4063 UM Principal Investigator
28. 2009 Innate Immune Receptors and Adjuvant Discovery NIH-DHHS-US-09-2413 UM Principal Investigator
29. 2008 2009 Supplement Request to: DNA-linked Dendrimer Nanoparticle Systems for Cancer Diagnosis and Treatment (R01 CA119409) NIH-DHHS-US-09-PAF00857. UM Principal Investigator
30. 2007 2009 007 AAAAI Clinical Fellowship in Allergy and Immunology American Academy of Allergy, A-07-0810 UM Principal Investigator
31. 2005 2009 Photonic Crystal Fiber Probe Fluorescence Biosensing NIH-DHHS-US-05-1462 UM Principal Investigator
32. 2004 2009 Apoptosis in Thyroiditis NIH-DHHS-US-04-1629 UM Principal Investigator
33. 2007 2008 Antimicrobial Soybean Oil-Based Nanoemulsion: Molecular Mechanism and Efficacy The United Soybean Board-07-4021. UM Principal Investigator
34. 2007 2008 Trivalent Bioterrorism Vaccine SubK-NIH-DHHS-US through a consortium with University of Chicago-07-2226 UM Principal Investigator
35. 2007 2008 Battlefield Analgesics with Physiological Feedback Control DARPA-DoD-US through a consortium with Army-DoD-US-07-2536. UM Principal Investigator
36. 2007 2008 A Chemical Sensitive RFID (Radio Frequency Identification) Sensor for Tracking Biological Warfare Agents SubK-AirForce-DoD-US through a consortium with Virtual EM Inc-07-4076 UM Principal Investigator
37. 2005 2008 Photonic Crystal Technology for Biomolecular Assay NIH-DHHS-US-05-1421. Participating Investigator with Specified Effort
38. 2003 2007 Targeted Magnetic Contrast Agent for MRI/SQUID Imaging NIH-DHHS-US-03-3413 UM Principal Investigator
39. 2003 2007 Polymer Platforms for Drug Delivery (MLSC# 03-580) MEDC-03-2922 UM Principal Investigator
40. 2004 2006 Development of a Novel Mucosal Vaccine for Anthrax SubK-NIH-DHHS-US through a consortium with University of Chicago-04-2766 Participating Investigator with Specified Effort
41. 2002 2006 Targeting Chemotherapeutic Drugs to Prostate Cancer Cells Using Dendrimers Coupled to Antiprostate-Specific Membrane Antigen (PSMA) Antibody Army-DoD-US-01-2979. UM Principal Investigator
42. 2002 2006 Novel Technologies for Noninvasive Detection, Diagnosis, and Treatment of Cancer NIH-DHHS-US-02-2478 UM Principal Investigator
43. 2001 2006 University of Michigan Surgical Oncology Research Training Program NIH-DHHS-US-01-0680. Participating Investigator with Specified Effort
44. 2001 2006 The University of Michigan Rheumatic Diseases Core Center NIH-DHHS-US-01-2895 Participating Investigator with Specified Effort
45. 2004 2005 Nanoscale Investigations of Membranes NIH-DHHS-US-05-0327 UM Principal Investigator
46. 2003 2005 Development of a Novel Vaccine for Small Pox SubK-NIH-DHHS-US through a consortium with University of Chicago-03-2211 UM Principal Investigator
47. 2002 2005 Biosensors for Real-Time Monitoring of Radiation-Induced Biologic Effects in Space NASA-US-01-3402 UM Principal Investigator
48. 2000 2005 Training of Allergy and Clinical Immunology Fellows NIH-DHHS-US-00-0360 UM Principal Investigator
49. 1999 2004 Apoptosis in Thyroiditis NIH-DHHS-US-98-3538 UM Principal Investigator
50. 1998 2004 Dysregulation of the Taurine Transporter - FIRST NIH-DHHS-US-98-0007 Participating Investigator with Specified Effort
51. 2002 2003 Shenai Hughes Predoctoral Fellowship Hughes, Howard Medical Inst.-02-3748 UM Principal Investigator
52. 2001 2002 Hormone Regulation of Apoptosis NIH-DHHS-US-01-3571 UM Principal Investigator
53. 1999 2002 Novel Technologies for Noninvasive Detection, Diagnosis and Treatment of Cancer NIH-DHHS-US-99-3062 UM Principal Investigator
54. 1998 2002 University of Michigan Multipurpose Arthritis and Musculoskeletal Disease Center NIH-DHHS-US-97-2182 Participating Investigator with Specified Effort
55. 1997 2002 Michigan Diabetes Research and Training Center NIH-DHHS-US-97-2573 Participating Investigator with Specified Effort
56. 1997 2002 Nanomolecule - Based Agents for Pathogen Counter Measure DARPA-DoD-US-97-0549 UM Principal Investigator
57. 1996 2002 NIH-DHHS-US-95-3046 NIH-DHHS-US-96-2928 Participating Investigator with Specified Effort
58. 2000 2001 Zeiss Laser Scanning Microscope (LSM) 501 Confocal Microscope System NIH-DHHS-US-99-2811 Participating Investigator with Specified Effort
59. 1999 2001 Mechanisms of Persistent Gene Expression with Adenovirus-Mediated Transfer NIH-DHHS-US-99-2258 Participating Investigator with Specified Effort
60. 1997 2001 Mucosal Gene Transfer Using Dendrimer Polymers NIH-DHHS-US-97-0055 UM Principal Investigator
61. 1996 2001 University of Michigan Surgical Oncology Research Training Program NIH-DHHS-US-95-3046 Participating Investigator with Specified Effort
62. 1997 2000 Gene Transfer and Gene Therapy in Allografting Baxter Healthcare Corporation-97-2716. Participating Investigator with Specified Effort
63. 1995 1999 An Open - Label, Randomized Study of Mycophenolate Mofetil for Treatment of Refactory Acute Cellular Roche Laboratories-95-2762 UM Principal Investigator
64. 1997 1998 A Randomized, Double - Blind, Placebo - Controlled, Multicenter Study Evaluating the Effect of Montelukast Compared to Inhaled Beclomethasone in Adult Asthmatic Patients Merck and Company, Inc.-98-0600 UM Principal Investigator
65. 1992 1998 Specialized Centers of Research - Rheumatoid Arthritis NIH-DHHS-US-92-1043 Participating Investigator with Specified Effort
66. 1997 1997 Development of Starburst Dendrimers as a Gene Transfer Agent Michigan Molecular Institute-97-2267 UM Principal Investigator
67. 1995 1997 Dendrimer Vector for Antisense Nucleotide Therapy of Cancer Pardee, Elsa U., Foundation-95-3592 UM Principal Investigator
68. 1993 1997 Long - Term Effects of Mycophenolate Mofetil in Renal Transplants Syntex (USA), LLC-93-3366 UM Principal Investigator
69. 1993 1997 University of Michigan Multipurpose Arthritis Center NIH-DHHS-US-92-2034 Participating Investigator with Specified Effort
70. 1996 1996 A Clinical Investigation to Assess the Acute Safety & Pharmacokinetics of Liquid Immune Globulin IV (Human) in Patients with Primary Immune Deficient Disease Baxter Healthcare Corporation-97-1822 Participating Investigator with Specified Effort
71. 1996 1996 Pfizer Protocol 154-135: Augmentin Clinical Trial Pharmco Inc.-96-3048. UM Principal Investigator
72. 1996 1996 Development of Starburst Dendrimers as a Gene Transfer Agent Michigan Molecular Institute-97-0079 UM Principal Investigator
73. 1995 1996 Development of Starburst Dendrimers as a Gene Transfer Agent Michigan Molecular Institute-95-3386 UM Principal Investigator
74. 1995 1996 Development of CEA (Carcinoembryonic Antigen) - Targeted Gene Transfer Vectors SubK-NIH-DHHS-US through a consortium with Dendritech, Inc.-95-2548. UM Principal Investigator
75. 1995 1996 Safety, Tolerance, Efficacy and Biological Half - Life of RPR 109413v and Gamimune N in Patients with Primary orSecondary Immune Deficiency Armour Pharmaceutical Company-96-0618 UM Principal Investigator
76. 1995 1996 Clinical Trial of Allervax Ragweed Immulogic Pharmaceutical Corp.-95-3376 UM Principal Investigator
77. 1995 1996 Long - Term Surveillance Study of Zileuton Vs. Usual Care in Patients w/Asthma Abbott Laboratories-95-1397. UM Principal Investigator
78. 1993 1996 Syntex Study IID 2176 (Randomized, Controlled, Dose Ranging Study of Myocophenolate Mofetil) Syntex (USA), LLC-94-0372 UM Principal Investigator
79. 1995 1995 Immune Responses to Thyroid Peroxidase NIH-DHHS-US-94-1876 UM Principal Investigator
80. 1995 1995 Immune Responses to Thyroid Peroxidase NIH-DHHS-US-95-2524 UM Principal Investigator
81. 1994 1995 Development of Starburst Dendrimers as a Gene Transfer Agent Michigan Molecular Institute-94-1641. UM Principal Investigator
82. 1994 1995 Characterization of the Tolerogenic Effects of ATGAM Upjohn Company, The-94-2691. Participating Investigator with Specified Effort
83. 1993 1995 Immune Response to Thyroid Peroxidase in Thyroid Cancer NIH-DHHS-US-92-3110 UM Principal Investigator
84. 1990 1995 Characterization of Thyroid Autoantibodies and Autoantigens NIH-DHHS-US-89-3076 UM Principal Investigator
85. 1993 1994 Characterization of the Toleroganic Effects of ATGAM Upjohn Company, The-93-2030 Participating Investigator with Specified Effort
86. 1992 1994 Mycophenolate Mofetil (RS-61443) Syntex Study #1868 Syntex (USA), LLC-93-0770 UM Principal Investigator
87. 1991 1994 Gene Therapy Approaches to Cystic Fibrosis Cystic Fibrosis Foundation-91-2759 Participating Investigator with Specified Effort
88. 1992 1992 University of Michigan Multipurpose Arthritis Center NIH-DHHS-US-92-2125 Participating Investigator with Specified Effort
89. 1991 1992 Characterization of Recognition Events Involved in the Genesis of Thyroid Autoimmunity Boots Pharmaceuticals, Inc.-92-2188 UM Principal Investigator
90. 1990 1991 Characterization of Recognition Events Involved in the Genesis of Thyroid Autoimmunity Boots Pharmaceuticals, Inc.-91-0238 UM Principal Investigator


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.